GLP‑1 Weight‑Loss Drugs Linked to Facial Changes, Hair Loss and Misuse Concerns

Weight‑loss medications that act as GLP‑1 receptor agonists, such as Ozempic, Wegovy, Mounjaro and Tirzepatide, have been associated with a range of side effects. Reported adverse effects include digestive problems, eye conditions like macular degeneration and non‑arteritic anterior ischaemic optic neuropathy, unexpected pregnancies, facial alterations such as sunken eyes, increased wrinkles and sagging skin, hair thinning, and even reduced shoe size after rapid weight loss. UK health authorities have warned that these drugs should not be used during pregnancy or when trying to conceive.

In addition to health risks, doctors in Spain have raised alarms about the drugs being used as a quick “bikini body” fix by people of normal weight. Endocrinologists note that the medications are approved only for obesity or overweight with related health conditions, and safety data for normal‑weight users are lacking. Sales of GLP‑1 drugs have surged, reflecting their growing popularity despite concerns about misuse and insufficient safety evidence for cosmetic use.